An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures

Vaccine

Volumn 33, Issue 35, 2015, Pages 4261-4268

  Pereira, Renata C ^a   Silva, Andrea N M R ^a   Souza, Marta Cristina O ^a   Silva, Marlon V ^a   Neves, Patrícia P C C ^a   Silva, Andrea A M V ^a   Matos, Denise D C S ^a   Herrera, Miguel A O ^a   Yamamura, Anna M Y ^a   Freire, Marcos S ^a   Gaspar, Luciane P ^a   Caride, Elena ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Inactivated vaccine; Protective response; Yellow fever

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROPIOLACTONE; YELLOW FEVER VACCINE; DISINFECTANT AGENT; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOREACTOR; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL RATE; VACCINE PRODUCTION; VERO CELL LINE; VIRUS NEUTRALIZATION; VIRUS PURIFICATION; VIRUS TITRATION; YELLOW FEVER VIRUS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHLOROCEBUS AETHIOPS; GROWTH, DEVELOPMENT AND AGING; HUMORAL IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; SERODIAGNOSIS; SURVIVAL ANALYSIS; VIROLOGY; VIRUS CULTURE; YELLOW FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOREACTORS; CERCOPITHECUS AETHIOPS; DISINFECTANTS; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; PROPIOLACTONE; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VERO CELLS; VIRUS CULTIVATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84939567661     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.077     Document Type: Article

References (40)

1. Kummerer B.M. The molecular biology of yellow fever virus. Molecular biology of the flavivirus 2006, 1-16. Cromwell Press, Norfolk, UK. M. Kalitzky, P. Borowski (Eds.).
2. Gardner C.L., Ryman K.D. Yellow fever: a reemerging threat. Clin Lab Med 2010, 30:237-260.
3. Monath T.P. Yellow fever: an update. Lancet Infect Dis 2001, 1:11-20.
4. Vasconcelos P.F. Febre amarela. Rev Soc Bras Med Trop 2003, 36(2):275-293.
5. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4:553-574.
6. Pugachev K.V., Guirakhoo F., Trent D.W., Monath T.P. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003, 33:567-582.
7. Franco O. Ministério da Saúde. Departamento Nacional de Endemias Rurais. História da febre amarela no Brasil 1976, Ministério da Saúde[[nl]]Ministry of Health, Rio de Janeiro, RJ.
8. Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010, 14(28):3827-3840.
9. Barrett A.D., Teuwen D.E. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol 2009, 21:308-313.
10. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358:91-97.
11. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012, 11:427-448.
12. Pato T.P., Souza M.C., Silva N.A., Pereira R.C., Silva M.V., Caride E., et al. Development of a membrane adsorber based capture step for the purification of yellow fever virus. Vaccine 2014, 24:2798-2893.
13. Simões M., Camacho L.A.B., Yamamura A.M.Y., Miranda E.H., Cajaraville A.C.R.A., Freire M.S. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 2012, 40:399-404.
14. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci 2004, 41:391-427.
15. Pugachev K.V., Guirakhoo F., Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005, 18:387-394.
16. Josefsberg J.O., Buckland B. Vaccine process technology. Biotechnol Bioeng 2012, 109:1443-1460.
17. Delrue I., Verzele D., Madder A., Nauwynck H.J. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 2012, 11:695-719.
18. Hindle E. A yellow fever vaccine. Br Med J 1928, 1(3518):976-977.
19. Gordon J.E., Hughes T.P. A study of inactivated yellow fever virus as immunizing agent. J Immunol 1936, 30:221-234.
20. Nathanson N., Langmuir A.D. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to cutter vaccine. Am J Hyg 1963, 78:29-60.
21. Juskewitch J.E., Tapia C.J., Windebank A.J. Lessons from the Salk polio vaccine: methods for and risks of rapid translation. Clin Transl Sci 2010, 3:182-185.
22. Uittenbogaard J.P., Zomer B., Hoogerhout P., Metz B. Reactions of β-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J Biol Chem 2011, 286:36198-36214.
23. Perez O., Paolazzi C.C. Production methods for rabies vaccine. J Ind Microbiol 1997, 18:340-347.
24. Stauffer F., El-Bacha T., Da Poian A.T. Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov 2006, 1:291-296.
25. Gaspar L.P., Mendes Y.S., Yamamura A.M., Almeida L.F., Caride E., Gonçalves R.B., et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008, 150:57-62.
26. Neves PC1, Santos J.R., Tubarão L.N., Bonaldo M.C., Galler R. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS ONE 2013, 8:e81953.
27. Schuller E., Klade C.S., Wolfl G., Kaltenbock A., Dewasthaly S., Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009, 27:2188-2193.
28. Zent O., Hennig R., Banzhoff A., Broker M. Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers. J Travel Med 2005, 12:85-93.
29. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011, 364:1326-1333.
30. Durbin A.P., Whitehead S.S. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338:129-143.
31. Monath T.P. Yellow fever vaccine. Vaccines 2004, 1095-1176. Elsevier, Philadelphia, PA. 4th ed. S. Plotkin, W.A. Orenstein (Eds.).
32. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccines 2006, 2:60-67.
33. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
34. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9:741-747.
35. Neves P.C., Rudersdorf R.A., Galler R., Bonaldo M.C., de Santana M.G., Mudd P.A., et al. CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 2010, 28:8183-8188. 29.
36. Monath T.P., Vasconcelos P.F.C. Yellow fever. J Clin Virol 2015, 64:160-173.
37. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
38. Hoft D.F., Brusic V., Sakala I.G. Optimizing vaccine development. Cell Microbiol 2011, 13:934-942.
39. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995, 25:823-829.
40. Dowd K.A., Pierson T.C. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 2011, 41:306-315.